Fifty 1 Labs, Inc. Eliminates 612 Million Shares from the Market

Rhea-AI Summary

Fifty 1 Labs (OTCID:FITY) retired 1,748,933 Series B preferred shares on April 14, 2026, permanently eliminating conversion rights for approximately 612,126,550 common shares.

The company used its own funds to repurchase and retire the preferred shares to treasury, aiming to reduce future dilution, strengthen capital structure, and improve the public float for shareholders.

Positive

• 612,126,550 potential common shares permanently removed from conversion
• Repurchase funded with company funds, avoiding new external dilution
• Repayment reduces future share overhang and may improve marketability of the float

Negative

• Use of internal funds to repurchase shares reduces cash reserves
• Conversion cleanup may not deliver immediate revenue or clinical progress

News Market Reaction – FITY

+40.00%

+40.00% Session close to close

In the Apr 14 session, FITY gained 40.00%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company Retires 1,748,933 Series B Preferred Shares, Permanently Blocking Conversion into 612,126,550 Common Shares - Bought Back with Company Funds

VANCOUVER, BC / ACCESS Newswire / April 14, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY), an AI-powered biotechnology company focused on peptide therapeutics, today announced the successful retirement of 1,748,933 shares of its Series B Preferred Stock.

This strategic move, completed using the Company's own funds in direct collaboration with the shareholder, permanently removes the potential for approximately 612,126,550 common shares from entering the market. By retiring these preferred shares back to treasury, Fifty 1 Labs has delivered a major win for existing shareholders by significantly reducing future dilution and strengthening the Company's capital structure.

This action is part of the Company's aggressive initiative to clean up its public vehicle, eliminate share overhang, and create a cleaner, more attractive foundation for sustainable growth and value creation.

Dr. Joel Gagnier, CEO of Fifty 1 Labs, commented: "This retirement of 1,748,933 Series B Preferred shares is a powerful demonstration of our commitment to protecting and enhancing shareholder value. Using our own resources to retire these shares means no new dilution, just a direct benefit to our investors. We've removed over 612 million potential common shares from the float, allowing us to focus fully on executing our vision in focused AI driven peptide therapeutics. We're grateful for the constructive partnership with the shareholder that made this possible, and we remain excited about empowering our community to 'Be Better Than Yesterday.'"

By proactively addressing potential dilution with internal funds, Fifty 1 Labs continues to streamline its operations, advance its innovative product pipeline in peptides and wellness, and position the Company for exciting growth opportunities ahead. Following the shareholder's latest conversion of the Series B Preferred shares, the Company made it a priority to repurchase and retire these shares to treasury using its own funds, thereby preventing any further dilution for existing shareholders.

About Fifty 1 Labs, Inc. Fifty 1 Labs, Inc. (OTC:FITY) is an AI-powered biotechnology and life sciences company focused on peptide products, peptide discovery, AI-enabled research, and clinical development. The Company is pursuing opportunities across musculoskeletal health, recovery, and performance through evidence-based innovation, strategic partnerships, and translational science.

Contact:
Investor Relations
Fifty1 Labs, Inc.
ir@fifty1labs.com | (877) 505-5006
www.fifty1labs.com

Forward-Looking Statements

Safe Harbor Statement:

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, identified by words such as "may," "will," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, involve risks and uncertainties that could cause actual results to differ materially from those projected. Such risks include, but are not limited to, general economic conditions, competition, technological changes, and other factors detailed in the company's Disclosure Statements. The company undertakes no obligation to update these statements.

SOURCE: Fifty 1 Labs, Inc.

View the original press release on ACCESS Newswire

FAQ

What did Fifty 1 Labs (FITY) do on April 14, 2026 regarding Series B preferred shares?

Fifty 1 Labs retired 1,748,933 Series B preferred shares on April 14, 2026. According to the company, the retirements permanently blocked conversion rights for about 612,126,550 common shares, removing a large potential source of dilution.

How does the FITY retirement of Series B shares affect potential dilution for shareholders?

The action permanently eliminates conversion of roughly 612,126,550 common shares, reducing potential dilution. According to the company, the repurchase and retirement were funded internally to prevent those shares from entering the market.

Did Fifty 1 Labs (FITY) use external financing to repurchase the preferred shares?

No, Fifty 1 Labs used its own funds to repurchase and retire the Series B preferred shares. According to the company, this avoided creating additional dilution through outside financing or new issuances.

What immediate shareholder benefits does the FITY share retirement provide?

Immediate benefits include a smaller potential float and reduced overhang from convertible shares. According to the company, this strengthens the capital structure and aims to make the public vehicle more attractive to investors.

Will the FITY repurchase of Series B shares create new dilution or change outstanding common shares?

No, the company says the retirement prevents conversion and creates no new dilution. According to the company, repurchasing the preferred shares to treasury permanently blocks approximately 612,126,550 potential common share conversions.